Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
Here is Why Jim Cramer Is Bullish About Merck (MRK)
We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...
Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip
Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...
Forget S&P 500 And Buy These Dividend Icons Instead
Read more on 2 durable dividend stocks that offer higher yields and strong cash flows, outperforming the S&P 500 in value, ...
Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!”
We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...
GlobalData on MSN13h
Big pharma faces headwinds in China as vaccine sales decline
Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.